Search results for: Institute for Clinical and Economic Review (ICER)
Filter search results
Uncertainty and Risk in HTA Decision Making
1 November 2016
…cost effectiveness analysis in respect of HTA in England and Wales, and the results of interviews with former decision makers at the National Institute for Health and Care Excellence (NICE)….
Dr Tuba Saygın Avşar
26 January 2024
…in Turkey. Tuba holds a PhD in Health Economics from the University of Birmingham and two master’s degrees in health economics and healthcare management. Her research focuses on health economics,…
Professor Dr Hasan Hüseyin Yildirim
26 January 2024
…over 150 peer-reviewed articles, books, and reports on critical issues in health policy and administration. Hasan’s recent work involves providing strategic guidance and technical support to governmental bodies on health…
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
…presentation (see below) discussed methods and processes for coordinating the assessment of diagnostics and treatments and urged that a consistent approach be developed and implemented. This was based in part…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
31 October 2017
…infections, such as overuse of antibiotics in human and veterinary care, and poor prevention and hygiene practices. On the other hand, the scarcity of new treatments, both recently launched as…
OHE Briefing on Incentives to Follow Best Practice in Health Care
27 February 2015
…and quality of evidence. In the second section, the authors describe incentives for best practice that are currently in place in the NHS, particularly in England, in primary and…
Opportunities for Utilising ‘Real World Data’ in South Korea
20 October 2017
…Health Insurance Review and Assessment Service (HIRA). Processes for data access and use are clear and maintain strong requirements for data protection. However, access tends to be limited to state,…
OHE at ISPOR Europe 2023
13 November 2023, 12:00am
…Long-Term Tracking of Clinical Effectiveness, Safety, and Value of Gene Therapies and Implications for EU Joint Clinical Assessment: Multistakeholder Perspectives From Patients, Manufacturers, and Payers Martina Garau (chair) 08:00 –…
Neil McAuslane
9 April 2025
…new medicines, building quality into the review process, decision making and HTA and regulatory alignment. He has edited and co-authored several publications and reports covering both regulatory and HTA topics….